TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental ...

- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...

NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company, is pleased to announce that it is scheduled to ...

SAN FRANCISCO--(BUSINESS WIRE)--Homeward ®, a company committed to rearchitecting the delivery of health and care in partnership with communities everywhere, starting in rural America, today announced ...

Le Bonheur’s risk-based innovation program Changing High-Risk Asthma in Memphis through Partnership (CHAMP) significantly decreased health care use related to asthma by targeting barriers to asthma ...